These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1002 related articles for article (PubMed ID: 22507745)

  • 21. [Germline mutations of TP53 gene among Chinese families with high risk for breast cancer].
    Yang X; Hu Z; Wu J; Liu G; Di G; Chen C; Hou Y; Huang X; Liu Z; Shen Z; Shao Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Dec; 32(6):761-5. PubMed ID: 26663043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
    Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
    Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next generation sequencing is informing phenotype: a TP53 example.
    O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
    Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TP53 germline mutations in adult patients with adrenocortical carcinoma.
    Herrmann LJ; Heinze B; Fassnacht M; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):E476-85. PubMed ID: 22170717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants.
    Inagaki-Kawata Y; Yoshida K; Kawaguchi-Sakita N; Kawashima M; Nishimura T; Senda N; Shiozawa Y; Takeuchi Y; Inoue Y; Sato-Otsubo A; Fujii Y; Nannya Y; Suzuki E; Takada M; Tanaka H; Shiraishi Y; Chiba K; Kataoka Y; Torii M; Yoshibayashi H; Yamagami K; Okamura R; Moriguchi Y; Kato H; Tsuyuki S; Yamauchi A; Suwa H; Inamoto T; Miyano S; Ogawa S; Toi M
    Commun Biol; 2020 Oct; 3(1):578. PubMed ID: 33067557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
    Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
    BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
    Blanco A; Graña B; Fachal L; Santamariña M; Cameselle-Teijeiro J; Ruíz-Ponte C; Carracedo A; Vega A
    Clin Genet; 2010 Feb; 77(2):193-6. PubMed ID: 19930417
    [No Abstract]   [Full Text] [Related]  

  • 29. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
    Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
    Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
    Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
    Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    da Silva PFF; Goveia RM; Teixeira TB; Gamba BF; de Lima AP; Rogatto SR; Silveira-Lacerda EP
    Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625568
    [No Abstract]   [Full Text] [Related]  

  • 33. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
    Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
    Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
    Zhang J; Sun J; Chen J; Yao L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Breast Cancer Res Treat; 2016 Aug; 158(3):455-62. PubMed ID: 27393621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
    Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
    Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inherited mutations in
    Wen WX; Allen J; Lai KN; Mariapun S; Hasan SN; Ng PS; Lee DS; Lee SY; Yoon SY; Lim J; Lau SY; Decker B; Pooley K; Dorling L; Luccarini C; Baynes C; Conroy DM; Harrington P; Simard J; Yip CH; Mohd Taib NA; Ho WK; Antoniou AC; Dunning AM; Easton DF; Teo SH
    J Med Genet; 2018 Feb; 55(2):97-103. PubMed ID: 28993434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2.
    Huusko P; Castrén K; Launonen V; Soini Y; Pääkkönen K; Leisti J; Vähäkangas K; Winqvist R
    Cancer Genet Cytogenet; 1999 Jul; 112(1):9-14. PubMed ID: 10432928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.